Bringing 'Undetectable = Untransmittable' messages into HIV counseling
Integrating U=U into HIV counseling: a cluster-randomized efficacy trial (INTUIT 2.0)
['FUNDING_R01'] · BOSTON UNIVERSITY MEDICAL CAMPUS · NIH-11192821
This project will see if a counseling app that explains 'Undetectable = Untransmittable (U=U)' helps people with HIV start and stay on treatment and reach undetectable viral loads.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY MEDICAL CAMPUS (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11192821 on ClinicalTrials.gov |
What this research studies
You would receive counseling at clinics in South Africa where some counselors use the 'Undetectable & You' app and others provide standard counseling. The app was co-created with people living with HIV and health providers and combines personal stories with clear science about U=U. About 880 people will be followed in a cluster-randomized trial, with surveys and viral load results collected through the National Health Laboratory Service to measure treatment adherence and viral suppression. The research team refined the app in a prior pilot before launching this larger effectiveness trial.
Who could benefit from this research
Good fit: Adults living with HIV who attend participating clinics in South Africa and are willing to receive counseling and share survey and lab data are ideal candidates.
Not a fit: People who do not attend the participating clinics or who are not interested in counseling or data-sharing would not directly benefit from joining this trial.
Why it matters
Potential benefit: If successful, this could reduce HIV stigma and help more people reach and maintain undetectable viral loads, lowering the risk of onward transmission.
How similar studies have performed: Prior evidence shows U=U messaging can reduce stigma and increase testing, and a prior pilot of the 'Undetectable & You' app supported moving to this larger randomized trial.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY MEDICAL CAMPUS — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOR, JACOB — BOSTON UNIVERSITY MEDICAL CAMPUS
- Study coordinator: BOR, JACOB
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus